Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$

HER	AMED LIMITED	
ABN 65 6	26 295 314	
We (th	ne entity) give ASX the following	information.
	1 - All issues st complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	N/A
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	N/A
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	N/A

Name of entity

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A
5	Issue price or consideration	N/A
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	N/A
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	29 May 2019
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 - 13,129,326 7.1A - 8,752,884	
7	⁺ Issue dates	NI / A	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	N/A	
	Cross reference: item 33 of Appendix 3B.		
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	Number 44,183,500	⁺ Class Fully paid ordinary shares

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
35,067,847	Fully paid ordinary shares escrowed until 12/12/20
8,277,494	Fully paid ordinary shares escrowed until 05/12/19
19,022,000	Options expiring 05/12/21 @ \$0.25 Escrowed until 12/12/20
927,504	Options expiring 05/12/21 @ \$0.00002 Escrowed until 12/12/20
2,743,655	Options expiring 05/12/21 @ \$0.00002 Escrowed until 05/12/19
4,578,000	Options expiring 05/12/21 @ \$0.25 Escrowed until 05/12/19

Deferred Consideration Shares:

The Company has agreed to issue up to 19,550,000 Shares as part consideration for the acquisition of the issued capital of Hera MED Ltd (Registration No. P.C. 51-467654-3) (HeraMED Israel), and up to 3,450,000 Shares to its corporate advisers, in each case subject to the satisfaction of certain performance milestones within 42 months of the date of quotation (Deferred Consideration Shares).

The Company confirms that if the performance milestones for the issue of the Deferred Consideration Shares are satisfied and the Deferred Consideration Shares are issued within 24 months of the date of quotation of the Company's securities on ASX, these securities will be restricted pursuant to the ASX Listing Rules for the periods below:

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

Number	+Class
4,871,874	Shares – First Milestone ¹ (Restriction period 24 months from date of quotation)
4,871,874	Shares – Second Milestone ² (Restriction period 24 months from date of quotation)
7,495,195	Shares – Third Milestone ³ (Restriction period 24 months from date of quotation)
1,628,126	Shares – First Milestone ¹ (Restriction period 12 months from date of quotation)
1,628,126	Shares – Second Milestone ² (Restriction period 12 months from date of quotation)
2,504,805	Shares – Third Milestone ³ (Restriction period 12 months from date of quotation)

Notes:

- 1. The applicable milestone is set out in sections 7.1(b)(ii)(A) and 7.2(a)(iv)(A) of the Prospectus.
- 2. The applicable milestone is set out in sections 7.1(b)(ii)(B) and 7.2(a)(iv)(B) of the Prospectus.
- 3. The applicable milestone is set out in sections 7.1(b)(ii)(C) and 7.2(a)(iv)(C) of the Prospectus.

10	Dividend policy (in the case of a	N/A
	trust, distribution policy) on the	,
	increased capital (interests)	

⁺ See chapter 19 for defined terms.

Part	2 - Pro rata issue	
11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the ⁺ securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
	of commission	
22	Names of any brokers to the issue	
	L	
23	Fee or commission payable to the	
	broker to the issue	
24	Amount of any handling fee	
	payable to brokers who lodge	
	acceptances or renunciations on behalf of security holders	
	benan or security notation	
25	If the issue is contingent on	
	security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be	
	sent to persons entitled	
27	If the entity has issued options, and the terms entitle option	
	holders to participate on exercise,	
	the date on which notices will be	
	sent to option holders	
28	Date rights trading will begin (if	
	applicable)	
29	Date rights trading will end (if	
	applicable)	
30	How do security holders sell their	
	entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i>	
	of their entitlements through a broker and accept for the	
	balance?	

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by nrough a broker)?	
33	⁺ Issue	e date	
Part	3 - C	Quotation of securit	ies
		omplete this section if you are app	
34	Type (of ⁺ securities one)	
(a)		⁺ Securities described in Part	1
(b)		All other ⁺ securities	
			d of the escrowed period, partly paid securities that become fully paid, n restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	at have ticked box 34(a)	
Addit	ional s	securities forming a new o	class of securities
Tick to docume		you are providing the informati	on or
35			securities, the names of the 20 largest holders of the ne number and percentage of additional *securities
36			securities, a distribution schedule of the additional nber of holders in the categories
37		A copy of any trust deed for the	ne additional ⁺ securities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of *securities for which ⁺quotation is sought

21,000

Yes

39 ⁺Class of ⁺securities for which quotation is sought

Fully paid ordinary shares

40 Do the *securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

> If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest or payment

Reason for request for quotation

Example: In the case of restricted securities, end of restriction period

41

now

(if issued upon conversion of another *security, clearly identify that other +security)

End of restriction period for 21,000 Fully paid ordinary shares on 13/06/19

Number +class 42 and of all ASX +securities quoted on (including the +securities in clause 38)

Number	+Class
44,183,500	Fully paid ordinary
	shares

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 14 June 2019

(Company secretary)

Print name: Stephen Buckley

== == == ==

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	87,528,841	
 Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	-	
"A"	87,528,841	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	13,129,326	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	-	
 Under an exception in rule 7.2 		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	-	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	13,129,326	
Note: number must be same as shown in Step 2		
Subtract "C"	-	
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"	13,129,326	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
87,528,841	
Step 2: Calculate 10% of "A"	
0.10	
Note: this value cannot be changed	
8,752,884	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
-	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	8,752,884
Note: number must be same as shown in Step 2	
Subtract "E"	-
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	8,752,884
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.